Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma

NCT00059904 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: aldesleukin
BIOLOGICAL: rituximab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]